Immunosuppression in Transplantation

Standard Triple Immunosuppression

Most solid organ transplant recipients receive a triple immunosuppression regimen consisting of:

Calcineurin Inhibitor

Tacrolimus (preferred) or Cyclosporine

Antimetabolite

Mycophenolate mofetil (MMF) or Azathioprine

Corticosteroid

Prednisone/Prednisolone (tapered over time)

Each agent targets a distinct step in T cell activation, providing synergistic immunosuppression while limiting the toxicity of any single agent.

Calcineurin Inhibitors (CNIs)

Tacrolimus (FK506) Cyclosporine (CsA)

Calcineurin inhibitors remain the cornerstone of transplant immunosuppression and have dramatically improved graft survival since their introduction in the 1980s.

Mechanism of Action:
Both CNIs inhibit the phosphatase calcineurin, preventing the dephosphorylation and nuclear translocation of NFAT (Nuclear Factor of Activated T cells).

Tacrolimus binds to FK-binding protein 12 (FKBP12) → tacrolimus-FKBP12 complex inhibits calcineurin.
Cyclosporine binds to cyclophilin (CyP) → CsA-CyP complex inhibits calcineurin.

Without calcineurin activity, NFAT cannot enter the nucleus → transcription of IL-2 and other cytokines is blocked → T cell activation and proliferation are suppressed.

Tacrolimus vs. Cyclosporine

Feature	Tacrolimus	Cyclosporine
Potency	~100× more potent than CsA	Standard
Rejection reduction	Superior (preferred agent)	Good
Nephrotoxicity	Significant (similar to CsA)	Significant
Neurotoxicity	Tremor, headache, PRES	Less common
Hirsutism / gingival hyperplasia	Not seen	Common cosmetic issues
Diabetes risk	Higher (PTDM)	Lower
Drug interactions	Extensive (CYP3A4/P-gp)	Extensive (CYP3A4)
Monitoring (trough)	Whole blood by LC-MS/MS	Whole blood C0 or C2

Monitoring Targets (Tacrolimus Whole Blood Trough Levels):

Early post-transplant (0–3 months): 8–12 ng/mL
Months 3–12: 6–10 ng/mL
Maintenance (>1 year): 4–8 ng/mL
Check trough level 12 hours after last dose, before next dose

CNI Adverse Effects:

Nephrotoxicity: Afferent arteriolar vasoconstriction → reduced GFR (acute, dose-dependent); chronic tubulointerstitial fibrosis (irreversible)
Hypertension: Via endothelin-1 upregulation and renin-angiotensin activation
Hyperkalemia and hypomagnesemia
Post-transplant diabetes mellitus (PTDM): Particularly tacrolimus — impairs insulin secretion
Neurotoxicity: Fine tremor, headache, seizures, PRES (posterior reversible encephalopathy syndrome)
Dyslipidemia (more with cyclosporine)

Mycophenolate Mofetil (MMF / CellCept)

Mycophenolate Mofetil (CellCept) Mycophenolic Acid (Myfortic)

Mycophenolate mofetil is the second pillar of triple immunosuppression, replacing azathioprine at most transplant centers due to superior rejection prophylaxis.

Mechanism: MMF is a prodrug hydrolyzed to mycophenolic acid (MPA), which reversibly inhibits inosine monophosphate dehydrogenase (IMPDH) — the rate-limiting enzyme in the de novo purine synthesis pathway. Lymphocytes (unlike most cells) rely almost exclusively on de novo purine synthesis for DNA replication (they lack the salvage pathway). Therefore, MPA selectively inhibits lymphocyte proliferation with relative sparing of other rapidly dividing cells. MPA also inhibits glycosylation of cell adhesion molecules, impairing lymphocyte recruitment to sites of inflammation.

Dosing and Monitoring:

MMF (CellCept): 1–1.5 g twice daily (total 2–3 g/day)
MPA (Myfortic EC tablets): 720 mg twice daily (bioequivalent)
Routine drug level monitoring is not standard; some centers monitor MPA AUC in high-risk patients
Monitor CBC for leukopenia (dose-reduce or switch to azathioprine if WBC <3,000)

Adverse Effects:

GI toxicity (most common): Nausea, vomiting, diarrhea, abdominal cramps — often dose-limiting; switching to EC-MPS (Myfortic) may improve GI tolerability
Leukopenia/neutropenia: Increased infection risk (CMV, fungal)
Anemia and thrombocytopenia
Teratogenicity (Category D): Absolute contraindication in pregnancy — causes ear malformations and other fetal defects; use contraception
CMV infection exacerbates MMF myelosuppression (bidirectional interaction)

mTOR Inhibitors (Sirolimus / Everolimus)

Sirolimus (Rapamune) Everolimus (Zortress / Certican)

mTOR inhibitors target a downstream kinase in the IL-2 signaling pathway. They are alternatives to CNIs (to minimize nephrotoxicity) and have additional antiproliferative properties useful for managing certain post-transplant complications.

Mechanism: Sirolimus (rapamycin) binds to FKBP12 — the same binding protein as tacrolimus, but the sirolimus-FKBP12 complex does NOT inhibit calcineurin. Instead, it inhibits mTOR complex 1 (mTORC1) — a serine/threonine kinase. mTORC1 is critical for cell cycle progression from G1 to S phase in response to IL-2 signaling. By blocking mTOR, sirolimus arrests T cell proliferation even in the presence of IL-2. It also has antiproliferative effects on B cells, NK cells, and smooth muscle cells (relevant for CAV prevention).

Dosing and Monitoring:

Sirolimus loading dose: 6 mg, then 2 mg/day; adjust to trough level
Target trough (combination with CNI): 4–8 ng/mL
Target trough (CNI-free): 8–15 ng/mL
Everolimus: 0.75–1.5 mg twice daily; target trough 3–8 ng/mL

Adverse Effects:

Wound healing impairment: Major concern — delay starting until wounds fully healed (typically >4–6 weeks post-transplant); avoid perioperatively
Dyslipidemia: Significant hyperlipidemia — statin therapy usually required
Proteinuria: Especially when combined with CNIs; can worsen pre-existing proteinuria
Mouth ulcers (aphthous stomatitis): Very common, dose-dependent
Pneumonitis: Interstitial pneumonitis — requires drug discontinuation
Leukopenia, thrombocytopenia
Edema (peripheral and lymphedema)

Clinical Indications

CNI minimization in patients with CNI nephrotoxicity
Prevention/treatment of BK virus nephropathy (immunosuppression reduction + mTOR switch)
Post-transplant malignancy (particularly KS and squamous cell carcinoma) — antiproliferative effect
Cardiac allograft vasculopathy (CAV) prophylaxis in heart transplants

Corticosteroids — Maintenance and Tapering

Corticosteroids are part of induction and maintenance immunosuppression but are tapered aggressively due to their extensive side effect profile. Many centers now practice steroid minimization or steroid-free protocols.

Mechanism: Bind glucocorticoid receptor → translocate to nucleus → transrepression of NF-kB (reduces IL-1, IL-2, IL-6, TNF-alpha, IFN-gamma) and transactivation of anti-inflammatory genes (annexin-1, IL-10). Reduce antigen presentation, lymphocyte trafficking, and monocyte activation.

Typical Tapering Protocol (Kidney Transplant)

Time Post-Tx	Prednisone Dose
Intraoperative	Methylprednisolone 500 mg IV
Day 1	Methylprednisolone 125 mg IV or Prednisone 30–60 mg PO
Week 1–2	Prednisone 30 mg/day
Month 1–3	Prednisone 15–20 mg/day
Month 3–6	Prednisone 10 mg/day
Month 6–12	Prednisone 5–7.5 mg/day
>1 year	Prednisone 5 mg/day or attempt steroid withdrawal (selected patients)

Long-term Steroid Adverse Effects:

Cushing syndrome (moon face, buffalo hump, truncal obesity)
Osteoporosis — supplement calcium 1000 mg + Vitamin D 800 IU daily; bisphosphonate if high risk
Glucose intolerance / diabetes
Hypertension, dyslipidemia, cardiovascular risk
Cataracts (posterior subcapsular)
Growth impairment in children
Adrenal insufficiency on rapid withdrawal
Avascular necrosis of femoral head

Belatacept (Nulojix) — Co-stimulation Blockade

Belatacept (Nulojix)

Belatacept is a fusion protein consisting of the extracellular domain of CTLA-4 linked to a modified Fc region of IgG1. It represents a mechanistically distinct approach to immunosuppression — targeting T cell co-stimulation rather than post-receptor signaling.

Mechanism (CTLA4-Ig / Co-stimulation Blockade):
Full T cell activation requires two signals:

Signal 1: TCR-MHC/peptide interaction (antigen recognition)
Signal 2 (co-stimulation): CD28 on T cell binds B7-1 (CD80) or B7-2 (CD86) on antigen-presenting cells

Belatacept's CTLA-4 domain binds B7-1 and B7-2 with higher affinity than CD28, blocking the CD28-B7 interaction. Without Signal 2, antigen-specific T cells undergo anergy (functional unresponsiveness) rather than activation. This induces antigen-specific tolerance while sparing bystander immunity to some degree.

Dosing Protocol (IV infusion, weight-based):

Initiation phase: 10 mg/kg on days 1 (transplant day), 5, end of weeks 2, 4, 8, and 12
Maintenance phase: 5 mg/kg every 4 weeks (indefinitely)
No therapeutic drug monitoring required (fixed weight-based dosing)

Clinical Role and Advantages

Provides renal-protective immunosuppression: improved eGFR vs. cyclosporine-based regimens (BENEFIT trial)
Suitable for patients with significant CNI nephrotoxicity or intolerance
No CNI nephrotoxicity, hypertension, or glucose intolerance from the drug itself
Demonstrated favorable long-term graft survival in selected patients

Key Safety Concern — PTLD Risk: Belatacept carries an FDA Black Box Warning for increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly CNS lymphoma, in EBV-seronegative recipients. It is contraindicated in EBV-seronegative patients. All recipients must be EBV IgG positive at transplantation. Additional adverse effects: increased risk of CMV, progressive multifocal leukoencephalopathy (PML), and other opportunistic infections compared to CNI-based regimens.

Drug Level Monitoring Reference

Drug	Sample Timing	Early (0–6 months)	Late (>12 months)	Units
Tacrolimus	12-hr trough	8–12	4–8	ng/mL (whole blood)
Cyclosporine (C0)	12-hr trough	150–250	75–125	ng/mL (whole blood)
Cyclosporine (C2)	2 hr post-dose	1000–1400	600–900	ng/mL (whole blood)
Sirolimus	24-hr trough	8–12 (if CNI-free)	5–8	ng/mL (whole blood)
Everolimus	12-hr trough	5–8	3–5	ng/mL (whole blood)

* Targets vary by center, organ type, time post-transplant, rejection history, and patient comorbidities. These represent common kidney transplant targets; other organs (heart, liver, lung) may differ.

Contents